Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

FibroBiologics, Inc. operates as an early stage, cell therapy company. The Company develops food and drug administration trials related to fibroblast treatments for degenerative disc disease, multiple sclerosis, cancer, wound healing, and other diseases. FibroBiologics serves clients in the United States.

<ul><li>On November 12, 2024, FibroBiologics, Inc. (FBLG) announced financial results for the third quarter of 2024 and provided a business update.</li><li>The company is continuing preparations for a Phase 1/2 clinical trial in Australia to test its fibroblast-based spheroid product as a therapy for diabetic foot ulcers.</li><li>We anticipate the trial initiating in the second quarter of 2025 and completing by the end of 2025.</li></ul>

On November 12, 2024, FibroBiologics, Inc. (FBLG) announced financial results for the third quarter of 2024 and provided a business update.The company is continuing preparations for a Phase 1/2 clinical trial in Australia to test its fibroblast-based spheroid product as a therapy for diabetic foot ulcers.We anticipate the trial initiating in the second quarter of 2025 and completing by the end of 2025.

FBLG: On Target to Initiate Phase 1/2 Trial in 2025 

Sadot Group Inc. operates as a global food supply chain group company. The Company offers services in sustainable farm operations, agri-commodity origination and trading operations for food and feed products such as soybean meal, wheat, and corn, and managing food service operations with a chain of restaurants. Sadot Group serves customers in the United States.

<ul><li>In late 2022, the company began its evolution from a consumer-focused, U.S. restaurant business into a global, food-focused organization with two distinct business units.</li><li>The company's largest operating unit is Sadot Agri-Foods, which is a vertically integrated international food supply chain company engaged in trading and shipping sustainable food and commodities such as soybeans, wheat and corn.</li><li>Sadot's legacy restaurant business is currently in the process of being divested.</li></ul>

In late 2022, the company began its evolution from a consumer-focused, U.S. restaurant business into a global, food-focused organization with two distinct business units.The company's largest operating unit is Sadot Agri-Foods, which is a vertically integrated international food supply chain company engaged in trading and shipping sustainable food and commodities such as soybeans, wheat and corn.Sadot's legacy restaurant business is currently in the process of being divested.

SDOT: Sadot Group reports 3rd quarter 2024 financial and operating results which showed strong growth in commodity related revenues.

Eltek Ltd. manufactures printed circuit boards, primarily multi-layer and flexrigid boards.  The Company's products are used as the core circuitry in sophisticated and compact electronic products.

<ul><li>Eltek Ltd is an established manufacturer of Printed Circuit Boards (PCBs) that is entering a new growth phase due to increases in manufacturing capacity and potential M&A transactions.</li><li>The company has the potential to grow both revenues and earnings at double-digit growth rates for the foreseeable future if they can execute on their accelerated investment program and maintain technological superiority.</li><li>The company maintains a strong balance sheet and generates free cash flow.</li></ul>

Eltek Ltd is an established manufacturer of Printed Circuit Boards (PCBs) that is entering a new growth phase due to increases in manufacturing capacity and potential M&A transactions.The company has the potential to grow both revenues and earnings at double-digit growth rates for the foreseeable future if they can execute on their accelerated investment program and maintain technological superiority.The company maintains a strong balance sheet and generates free cash flow.

ELTK:  Eltek releases 3rd quarter 2024 financial results. The company also provided updates on end market trends and its capacity improvement program.  We maintain our price target of 18.00 per share.

SBC Medical Group Holdings  / Equity Bottom-Up

SBC Medical Group Holdings Incorporated operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

<ul><li>Singapore's economy has expanded significantly over the past two decades.</li><li>GDP was above US$466 billion in 2022, according to the World Bank, which also notes that the "country provides one of the world's most business-friendly regulatory environments for local entrepreneurs and is ranked among the world's most competitive economies." Moreover, reflecting its strategic location, economic growth & business friendly climate, Singapore attracts substantial amounts of U.S. foreign direct investment (FDI), factors that likely portend well for increasing demand for aesthetic services, in our view.</li></ul>

Singapore's economy has expanded significantly over the past two decades.GDP was above US$466 billion in 2022, according to the World Bank, which also notes that the "country provides one of the world's most business-friendly regulatory environments for local entrepreneurs and is ranked among the world's most competitive economies." Moreover, reflecting its strategic location, economic growth & business friendly climate, Singapore attracts substantial amounts of U.S. foreign direct investment (FDI), factors that likely portend well for increasing demand for aesthetic services, in our view.

SBC: Agreement to Acquire Singapore's AHH Furthers Emerging International Expansion

Cadrenal Therapeutics  / Equity Bottom-Up

Cadrenal Therapeutics, Inc. operates as a biotech company. The Company focuses on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation. Cadrenal Therapeutics serves customers worldwide.

<ul><li>On November 7, 2024, Cadrenal Therapeutics, Inc. (CVKD) announced financial results for the third quarter of 2024 and provided a business update.</li><li>The company recently raised approximately $9.8 million, which included $5.1 million raised through its at-the-market (ATM) facility and $4.7 million through warrant exercises.</li><li>Cadrenal recently met with the FDA to discuss the protocol for the planned Phase 3 clinical trial of tecarfarin in left ventricular assist device (LVAD) patients and those discussions are continuing.</li></ul>

On November 7, 2024, Cadrenal Therapeutics, Inc. (CVKD) announced financial results for the third quarter of 2024 and provided a business update.The company recently raised approximately $9.8 million, which included $5.1 million raised through its at-the-market (ATM) facility and $4.7 million through warrant exercises.Cadrenal recently met with the FDA to discuss the protocol for the planned Phase 3 clinical trial of tecarfarin in left ventricular assist device (LVAD) patients and those discussions are continuing.

CVKD: Recent Financings Raise 9.8 Million 